$DMTKQ
DermTech Inc

2019 Q2 Form 10-K Financial Statement

#000119312519173682 Filed on June 14, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q1 2018
Revenue $614.0K $0.00 $2.442M
YoY Change
Cost Of Revenue $2.627M
YoY Change
Gross Profit -$72.00K -$185.0K
YoY Change
Gross Profit Margin -11.73% -7.58%
Selling, General & Admin $2.738M
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $100.0K $76.00K
YoY Change
% of Gross Profit
Operating Expenses $3.256M $81.75K $306.2K
YoY Change 1958.54% 510305.0%
Operating Profit -$3.328M -$8.560M
YoY Change 2004.07% 14266566.67%
Interest Expense -$324.0K $470.0K -$1.093M
YoY Change -154.0% -194.22%
% of Operating Profit
Other Income/Expense, Net -$40.00K -$1.444M
YoY Change
Pretax Income -$140.0K $390.0K $940.0K
YoY Change -131.82% 9.3%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.692M -$2.281M -$10.00M
YoY Change 63.87% 16673233.33%
Net Earnings / Revenue -601.3% -409.66%
Basic Earnings Per Share
Diluted Earnings Per Share -$26.62K $76.77K $182.9K
COMMON SHARES
Basic Shares Outstanding 5.343M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2018 Q1 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $400.0K $0.00
YoY Change -100.0% -100.0%
Cash & Equivalents $15.28K $449.9K
Short-Term Investments
Other Short-Term Assets $0.00 $100.0K $100.0K
YoY Change -100.0% 0.0%
Inventory
Prepaid Expenses $45.75K $93.50K
Receivables
Other Receivables
Total Short-Term Assets $61.03K $543.4K $100.0K
YoY Change -86.53% 2073.78% -80.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $12.40M $146.4M $12.40M
YoY Change -91.56% -91.53%
Other Assets $0.00
YoY Change
Total Long-Term Assets $12.43M $146.4M $12.30M
YoY Change -91.54% 86119.17% -91.6%
TOTAL ASSETS
Total Short-Term Assets $61.03K $543.4K $100.0K
Total Long-Term Assets $12.43M $146.4M $12.30M
Total Assets $12.49M $146.9M $12.40M
YoY Change -91.52% 75329.85% -91.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.400M $0.00 $1.500M
YoY Change 2300.0%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.469M $41.95K $6.600M
YoY Change 2150.07% -75.69% 29.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.469M $41.95K $6.600M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $6.782M $5.073M $6.600M
YoY Change 31.91% 2840.39% 29.41%
SHAREHOLDERS EQUITY
Retained Earnings $1.659M $853.6K
YoY Change 27.89% -30662.62%
Common Stock $3.341M $4.146M
YoY Change -9.77% 16485.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.69M $1.459M $5.900M
YoY Change
Total Liabilities & Shareholders Equity $12.49M $146.9M $12.40M
YoY Change -91.52% 75329.85% -91.56%

Cashflow Statement

Concept 2019 Q2 2018 Q1 2018
OPERATING ACTIVITIES
Net Income -$3.692M -$2.281M -$10.00M
YoY Change 63.87% 16673233.33%
Depreciation, Depletion And Amortization $100.0K $76.00K
YoY Change
Cash From Operating Activities -$25.71K -$100.0K -$7.605M
YoY Change -60.07% -346727.16%
INVESTING ACTIVITIES
Capital Expenditures $12.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $136.9M
YoY Change -194.3%
Cash From Investing Activities $0.00 -$12.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.50K 0.000 11.13M
YoY Change 174731.11%
NET CHANGE
Cash From Operating Activities -25.71K -100.0K -7.605M
Cash From Investing Activities 0.000 -12.00K
Cash From Financing Activities 10.50K 0.000 11.13M
Net Change In Cash -15.21K -100.0K 3.511M
YoY Change -76.38% 40921.15%
FREE CASH FLOW
Cash From Operating Activities -$25.71K -$100.0K -$7.605M
Capital Expenditures $12.00K
Free Cash Flow -$7.617M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30487
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
449942
CY2019Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
51257
CY2018Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
93503
CY2019Q1 us-gaap Assets Current
AssetsCurrent
81744
CY2018Q1 us-gaap Assets Current
AssetsCurrent
543445
CY2019Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
12357980
CY2018Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
146350150
CY2019Q1 us-gaap Assets
Assets
12439724
CY2018Q1 us-gaap Assets
Assets
146893595
CY2019Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1522158
CY2018Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
30853
CY2019Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
36095
CY2018Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
11095
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1558253
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
41948
CY2019Q1 cnacu Deferred Underwriting Fees Noncurrent
DeferredUnderwritingFeesNoncurrent
5031250
CY2018Q1 cnacu Deferred Underwriting Fees Noncurrent
DeferredUnderwritingFeesNoncurrent
5031250
CY2019Q1 us-gaap Liabilities
Liabilities
6589503
CY2018Q1 us-gaap Liabilities
Liabilities
5073198
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
850217
CY2018Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
136820396
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
3201932
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
4146387
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1798072
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
853614
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
5000004
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
5000001
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12439724
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146893595
CY2017Q2 cnacu Deferred Underwriting Fees
DeferredUnderwritingFees
5031250
CY2017Q2 cnacu Deferred Fees Related To Third Parties Description
DeferredFeesRelatedToThirdPartiesDescription
Of such amount, up to approximately 0.5% per Unit, or $718,750, may be paid to third parties not participating in the Initial Public Offering that assist the Company in consummating its Business Combination.
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5260831
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5091071
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5260831
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5091071
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q3 cnacu Financial Advisory Agreement Success Fee Percentage
FinancialAdvisoryAgreementSuccessFeePercentage
0.015
CY2018Q3 cnacu Financial Advisory Agreement Additional Fees Percentage
FinancialAdvisoryAgreementAdditionalFeesPercentage
0.005
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019 us-gaap Operating Expenses
OperatingExpenses
1978028
CY2018 us-gaap Operating Expenses
OperatingExpenses
306243
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-1978028
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-306243
CY2019 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2863123
CY2018 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1208066
CY2019 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
59363
CY2018 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-45416
CY2019 us-gaap Net Income Loss
NetIncomeLoss
944458
CY2018 us-gaap Net Income Loss
NetIncomeLoss
856407
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5136904
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4721185
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.14
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2019Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
81701
CY2018Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
13438929
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
22207
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
135329283
CY2018 cnacu Stock Issued During Period Value Under Private Placement
StockIssuedDuringPeriodValueUnderPrivatePlacement
5612500
CY2018 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
136820396
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
5000004
CY2019Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
81701
CY2018Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
13438929
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
2863101
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
1208066
CY2019 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
59363
CY2018 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-45416
CY2019 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-42246
CY2018 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
93503
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1491305
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
26355
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-444455
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-373391
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
145187500
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
136914634
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-145187500
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
140875000
CY2018 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
5612500
CY2019 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
25000
CY2018 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
162255
CY2018 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
319197
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-136889634
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
145985833
CY2019 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-419455
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
424942
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
449942
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30487
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
449942
CY2019 cnacu Offering Cost Charge To Additional Capital
OfferingCostChargeToAdditionalCapital
0
CY2018 cnacu Offering Cost Charge To Additional Capital
OfferingCostChargeToAdditionalCapital
301278
CY2019 cnacu Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
0
CY2018 cnacu Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
5031250
CY2019 cnacu Classification Of Ordinary Shares Subject To Possible Redemption
ClassificationOfOrdinarySharesSubjectToPossibleRedemption
0
CY2018 cnacu Classification Of Ordinary Shares Subject To Possible Redemption
ClassificationOfOrdinarySharesSubjectToPossibleRedemption
135963594
CY2019 cnacu Change In Value Of Ordinary Shares Subject To Possible Redemption
ChangeInValueOfOrdinarySharesSubjectToPossibleRedemption
944455
CY2018 cnacu Change In Value Of Ordinary Shares Subject To Possible Redemption
ChangeInValueOfOrdinarySharesSubjectToPossibleRedemption
856802
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 18pt; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates </div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated&#160;financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated&#160;financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated&#160;financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from our estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 18pt; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentration of credit risk </div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000. The Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.50
CY2019 cnacu Withdrawal From Trust For Redemption Of Ordinary Shares
WithdrawalFromTrustForRedemptionOfOrdinaryShares
136914634
CY2017Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
5612500
CY2018 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
5612500
CY2019 cnacu Payments For Redemption Of Ordinary Shares
PaymentsForRedemptionOfOrdinaryShares
136914634
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
344725
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2018 cnacu Withdrawal From Trust For Redemption Of Ordinary Shares
WithdrawalFromTrustForRedemptionOfOrdinaryShares
0
CY2017Q2 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
10000
CY2019 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2018 cnacu Payments For Redemption Of Ordinary Shares
PaymentsForRedemptionOfOrdinaryShares
0
CY2019Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
36095
CY2018Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
11095
CY2019 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2017Q2 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
Each Unit consists of one Public Share, one right and one redeemable warrant ("Public Warrant"). Each right will convert into one-tenth (1/10) of one ordinary share. Each Public Warrant entitles the holder to purchase one-half (1/2) of one ordinary share at an exercise price of $11.50 per whole share.
CY2019Q1 us-gaap Investment Company Distributable Earnings Loss Accumulated Capital Loss Carryforward
InvestmentCompanyDistributableEarningsLossAccumulatedCapitalLossCarryforward
1500000
CY2019Q1 us-gaap Cash
Cash
30000
CY2019 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
364000
CY2019Q1 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
13187468
CY2019Q1 cnacu Payments For Redemption Of Ordinary Shares
PaymentsForRedemptionOfOrdinaryShares
136900000
CY2017Q2 cnacu Dissolution Expenses
DissolutionExpenses
50000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
944458
CY2018 us-gaap Net Income Loss
NetIncomeLoss
856407
CY2019 us-gaap Dilutive Securities
DilutiveSecurities
-201067
CY2018 us-gaap Dilutive Securities
DilutiveSecurities
-1086961
CY2019 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
743391
CY2018 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-230554
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5136904
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4721185
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.14
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2019Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5342532
CY2018 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
0
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
5000001
CY2019 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
944455
CY2019 us-gaap Professional Fees
ProfessionalFees
120000
CY2018 us-gaap Professional Fees
ProfessionalFees
90000
CY2017Q2 cnacu Deferred Fee On Gross Proceeds Of Initial Public Offering Percentage
DeferredFeeOnGrossProceedsOfInitialPublicOfferingPercentage
-0.035
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5260831
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5260831
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5091071
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5091071
CY2017Q2 cnacu Founder Shares Forfeited
FounderSharesForfeited
136250
CY2017Q2 us-gaap Stock Issued1
StockIssued1
1362500
CY2017Q2 us-gaap Share Price
SharePrice
10.00
CY2017Q2 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
Each holder of a right will receive one-tenth (1/10) of one ordinary share upon consummation of a Business Combination, even if the holder of such right redeemed all shares held by it in connection with a Business Combination.
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Entity Registrant Name
EntityRegistrantName
Constellation Alpha Capital Corp.
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001651944
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q3 dei Entity Public Float
EntityPublicFloat
116400000
CY2019 dei Trading Symbol
TradingSymbol
CNACU
CY2019 dei Entity Shell Company
EntityShellCompany
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019 dei Entity Small Business
EntitySmallBusiness
true

Files In Submission

Name View Source Status
0001193125-19-173682-index-headers.html Edgar Link pending
0001193125-19-173682-index.html Edgar Link pending
0001193125-19-173682.txt Edgar Link pending
0001193125-19-173682-xbrl.zip Edgar Link pending
cnacu-20190331.xml Edgar Link completed
cnacu-20190331.xsd Edgar Link pending
cnacu-20190331_cal.xml Edgar Link unprocessable
cnacu-20190331_def.xml Edgar Link unprocessable
cnacu-20190331_lab.xml Edgar Link unprocessable
cnacu-20190331_pre.xml Edgar Link unprocessable
d760850d10k.htm Edgar Link pending
d760850dex311.htm Edgar Link pending
d760850dex312.htm Edgar Link pending
d760850dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending